| アブストラクト | BACKGROUND: Antibody-drug conjugates (ADCs) are gaining widespread use in the treatment of breast cancer, although toxicity remains an underexplored issue in the real-world clinical setting. Individual case safety reports collected in large pharmacovigilance databases can advance our knowledge on their safety profile in routine clinical practice. OBJECTIVE: We prioritized adverse events (AEs) reported with ADCs approved for breast cancer using the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We assessed clinical priority of AEs reported in FAERS (February 2013-March 2022) for trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG) by attributing a score to each AE disproportionally reported with ADCs. Four criteria were assessed: clinical relevance, reporting rate, reported case fatality rate, and stability of disproportionality signals (consistency of the reporting odds ratio across multiple analyses using three different comparators). RESULTS: We retained 6589 reports (77.4% referring to T-DM1 as suspect), and 572 AEs generated a disproportionality signal in at least one analysis. The majority of these AEs (62%) were classified as moderate clinical priorities (e.g., interstitial lung disease with T-DXd, thrombocytopenia, peripheral neuropathy with T-DM1, febrile neutropenia, and large intestine perforation with SG). Three AEs emerged as high clinical priorities (6 points): septic shock and neutropenic colitis with SG (N = 8 and 13, with median onset 13 and 10 days, respectively), without co-reported immunosuppressive agents; and pulmonary embolism with T-DM1 (N = 31, median onset 109 days, 52% with reported metastasis). CONCLUSION: The heterogeneous spectrum of post-marketing toxicities for ADCs used in breast cancer, as emerging from the FAERS, is largely in line with preapproval evidence. Although causality cannot be proved, we call for increased awareness by oncologists on potential serious unexpected reactions, including early onset of septic shock and neutropenic colitis with SG, and late emergence of pulmonary embolism with T-DM1. |
|---|
| ジャーナル名 | Targeted oncology |
|---|
| Pubmed追加日 | 2024/5/2 |
|---|
| 投稿者 | Cecco, Sara; Puligheddu, Stefano; Fusaroli, Michele; Gerratana, Lorenzo; Yan, Miao; Zamagni, Claudio; De Ponti, Fabrizio; Raschi, Emanuel |
|---|
| 組織名 | Hospital Pharmacy Unit-CRO Aviano, National Cancer Institute, IRCCS, 33081,;Aviano, PN, Italy. scecco@cro.it.;Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of;Bologna, Bologna, Italy.;Department of Medical Oncology-CRO Aviano, National Cancer Institute, IRCCS,;Aviano, Italy.;Department of Pharmacy, The Second Xiangya Hospital, Central South University,;Changsha, China.;International Research Center for Precision Medicine, Transformative Technology;and Software Services, Changsha, China.;Toxicology Counseling Center of Hunan Province, Changsha, China.;IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38696126/ |
|---|
